X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - Clinical Trials News - 03/Jul 04:07

First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

GAITHERSBURG, Md., July 02, 2024. artesian Therapeutics, Inc. (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the first patient has been dosed in its...

Articles similaires

Sorry! Image not available at this time

Cartesian Therapeutics doses first patient in phase 2 clinical trial of Descartes─08 to treat systematic lupus erythematosus

pharmabiz.com - 04/Jul 00:00

Cartesian Therapeutics, Inc, a clinical─stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first...

Sorry! Image not available at this time

First Patient Dosed in the MAD Part 2 Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

drugs.com - 26/Jun 19:06

CAMBRIDGE, Mass., June 26, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...

Sorry! Image not available at this time

Immunocore: Research Scientist - Autoimmune Diseases

pharmiweb.com - 25/Jun 10:06

GBP34000 - GBP40000 per year: Immunocore: Immunocore (NASDAQ: IMCR) is a pioneering, commercial-stage T cell receptor biotechnology company whose...

Sorry! Image not available at this time

EG 427 receives US FDA clearance to initiate phase 1b/2a study of gene therapy, EG110A to treat NDO in spinal cord injury patients

pharmabiz.com - 26/Jun 00:00

EG 427, a biotechnology company leading the development of pinpoint DNA medicines for prevalent diseases in neurology based on its unique...

Sorry! Image not available at this time

Immunocore: Principal Research Scientist - In Silico Biologics Design

pharmiweb.com - 03/Jul 11:57

GBP75000 - GBP90000 per year: Immunocore: Immunocore (NASDAQ: IMCR) is a pioneering, commercial-stage T cell receptor biotechnology company whose...

Sorry! Image not available at this time

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study

zacks.com - 27/Jun 14:26

Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin...

Sorry! Image not available at this time

Barrington James: Senior CRA

pharmiweb.com - 25/Jun 00:00

Competitive: Barrington James: Sr. Clinical Research Associate - Biomimetic TAVR Valve (Europe) The Company The Company is a pioneering MedTech...

Sorry! Image not available at this time

Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg

drugs.com - 02/Jul 04:07

DAEJEON, South Korea, July 2, 2024. PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing...

Sorry! Image not available at this time

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

varabnewsexpress.ae  - 04/Jul 07:13

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B...

Sorry! Image not available at this time

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

qatarnewswire.qa - 04/Jul 07:13

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B...

Les derniers communiqués